Investing Profile

Lorence Kim

InvestorVC
Venture Partner at Third Rock Ventures
thirdrockventures.com/people/...Cambridge, Massachusetts
Photo of Lorence Kim, Venture Partner at Third Rock Ventures

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Harvard University Network
259 CONNECTIONS
University of Pennsylvania - The Wharton School Network
216 CONNECTIONS
Goldman Sachs Network
191 CONNECTIONS
cb
Third Rock Ventures Venture Partner
$100K - $5.0M
$1.5M
5
$770M
CompanyStageDateRound SizeTotal Raised
Triana Biomedicines
Series BDec 2025$120M
$230M
Co-investors: Christopher O'Donnell (Pfizer Venture Investments)
Tubulis
Series COct 2025$400M
$620M
Co-investors: Sofia Ioannidou (Andera Partners), Sebastian Pünzeler (Coparion), Patrick Heron (Frazier Healthcare Partners)
Odyssey Therapeutics
Series CDec 2023$100M
$490M
Co-investors: Elena Viboch (General Catalyst), Carl Gordon (OrbiMed)
ADARx Pharmaceuticals
Series CAug 2023$200M
Series BJan 2023$46M
$320M
Co-investors: Carl Gordon (OrbiMed)
Board Member Cowen Inc.2022 - 2023
Venture Partner Third Rock Ventures2020 - 2022
Board Member Seres Therapeutics2014 - 2020
Chief Financial Officer Moderna2014 - 2020
Managing Director Goldman Sachs2000 - 2014
Co-founder and Managing Partner Ascenta Capital2023 - Present
Board Member AmerisourceBergen2022 - Present
Board Member REVOLUTION Medicines2022 - Present
Board Member Abata Therapeutics2021 - Present
Board Member Flare Therapeutics2021 - Present
University of Pennsylvania - The Wharton School MBA Healthcare Management
University of Pennsylvania School of Medicine Doctor of Medicine (MD)
Harvard University AB, magna cum laude Biochemical Sciences